Nuvation Bio Inc. Debt Securities, Available-for-sale
Nuvation Bio Inc. (NUVB) had Debt Securities, Available-for-sale of $422.70 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale $422.70M.
- 2026-03-31: Debt Securities, Available-for-sale $495.97M.
- 2025-12-31: Debt Securities, Available-for-sale $461.45M.
- 2025-09-30: Debt Securities, Available-for-sale $529.26M.
| Period end | Debt Securities, Available-for-sale | Debt Securities, Available-for-sale as first filed |
|---|---|---|
| 2026-06-30 | $422.70M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $495.97M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $461.45M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $529.26M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $558.74M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $429.60M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $478.52M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $528.24M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $562.44M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $585.23M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $595.07M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $614.85M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $605.58M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $644.20M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $628.23M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $655.12M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $671.16M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $682.68M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $717.68M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $447.15M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $357.07M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $185.81M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $196.40M 10-K · filed 2022-02-28 | $186.00M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |